All Stories

  1. Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

    Article • Blood and Lymphatic Cancer Targets and Therapy, March 2016, Dove Medical Press

    alex almasan, Dr Mitchell R Smith, Dr Yazan Madanat

  2. Bortezomib for the treatment of mantle cell lymphoma

    Article • Expert Opinion on Orphan Drugs, October 2014, Informa Healthcare

    Dr Mitchell R Smith

  3. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways

    Article • British Journal of Haematology, October 2014, Wiley

    Dr Mitchell R Smith

  4. A phase 1 dose-escalation study of XmAb®2513 in patients with relapsed or refractory Hodgkin lymphoma

    Article • British Journal of Haematology, October 2014, Wiley

    Dr Mitchell R Smith

  5. Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

    Article • Leukemia & Lymphoma, July 2014, Taylor & Francis

    Dr Mitchell R Smith

  6. Allogeneic Transplantation for Lymphoma: Risk-Benefit Balance Is in the Eye of the Beholder

    Article • Biology of Blood and Marrow Transplantation, July 2014, Elsevier

    Dr Mitchell R Smith

  7. Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex®system

    Article • British Journal of Haematology, June 2014, Wiley

    Dr Mitchell R Smith

  8. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study

    Article • British Journal of Haematology, April 2014, Wiley

    Dr Mitchell R Smith

  9. Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin

    Article • Leukemia & Lymphoma, April 2014, Taylor & Francis

    Dr Mitchell R Smith

  10. New agents for the treatment of lymphoid leukemia and lymphoma: focus on recent FDA approvals

    Article • Discoveries, March 2014, Applied Systems, srl

    Dr Mitchell R Smith, alex almasan

  11. Lymphoma Takeaways from ASH2013

    Article • Oncology Times, February 2014, Wolters Kluwer Health

    Dr Mitchell R Smith

  12. ASH Annual Meeting

    Article • Oncology Times, February 2014, Wolters Kluwer Health

    Dr Mitchell R Smith

  13. Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line

    Article • British Journal of Haematology, January 2014, Wiley

    Dr Mitchell R Smith

  14. Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma

    Article • Leukemia Research, October 2013, Elsevier

    Dr Mitchell R Smith

  15. ASH Annual Meeting

    Article • Oncology Times, February 2013, Wolters Kluwer Health

    Dr Mitchell R Smith

  16. ASH Annual Meeting

    Article • Oncology Times, February 2013, Wolters Kluwer Health

    Dr Mitchell R Smith

  17. A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study

    Article • Leukemia & Lymphoma, January 2013, Taylor & Francis

    Dr Mitchell R Smith

  18. Parametric Model of Combination Therapy for Non-Hodgkin Lymphoma

    Article • PLoS ONE, December 2012, PLOS

    Dr Mitchell R Smith

  19. Radioimmunotherapy in mantle cell lymphoma

    Article • Best Practice & Research Clinical Haematology, June 2012, Elsevier

    Dr Mitchell R Smith

  20. Management of mantle cell lymphoma in the elderly

    Article • Best Practice & Research Clinical Haematology, June 2012, Elsevier

    Dr Mitchell R Smith

  21. Tetanus toxoid reactive lymphadenopathy masquerading as T-cell lymphoma

    Article • Future Oncology, May 2012, Future Medicine

    Dr Mitchell R Smith

  22. Brentuximab vedotin in anaplastic large cell lymphoma

    Article • Expert Opinion on Biological Therapy, March 2012, Informa Healthcare

    Dr Mitchell R Smith

  23. Should there be a standard therapy for mantle cell lymphoma?

    Article • Future Oncology, February 2011, Future Medicine

    Dr Mitchell R Smith

  24. Tackling mantle cell lymphoma (MCL): Potential benefit of allogeneic stem cell transplantation

    Article • Stem Cells and Cloning Advances and Applications, July 2010, Taylor & Francis

    Dr Mitchell R Smith

  25. Gastric Mucosa-Associated Lymphoid Tissue Lymphoma

    Article • Seminars in Oncology, June 2010, Elsevier

    Dr Mitchell R Smith

  26. Extranodal NK/T-cell lymphoma nasal type: Efficacy of pegaspargase. Report of two patients from the United Sates and review of literature

    Article • Leukemia Research, January 2010, Elsevier

    Dr Mitchell R Smith

  27. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

    Article • British Journal of Haematology, November 2008, Wiley

    Dr Mitchell R Smith

  28. Cutaneous Precursor B-Cell Lymphoblastic Lymphoma in 2 Adult Patients

    Article • Archives of Dermatology, September 2008, American Medical Association (AMA)

    Dr Mitchell R Smith

  29. Mantle cell lymphoma: advances in biology and therapy

    Article • Current Opinion in Hematology, July 2008, Wolters Kluwer Health

    Dr Mitchell R Smith

  30. Antibodies and Hematologic Malignancies

    Article • The Cancer Journal, May 2008, Wolters Kluwer Health

    Dr Mitchell R Smith

  31. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature

    Article • Leukemia & Lymphoma, January 2006, Taylor & Francis

    Dr Mitchell R Smith

  32. Comment on “Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study,” by Kahl et al.,Cancer Investig.igation, 2005, 23(1), pp. 13–18

    Article • Cancer Investigation, January 2005, Taylor & Francis

    Dr Mitchell R Smith

  33. Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma

    Article • Cancer, October 2004, Wiley

    Dr Mitchell R Smith

  34. Phase II Study of PEND Chemotherapy in Patients with Refractory/Relapsed Hodgkin Lymphoma

    Article • Leukemia & Lymphoma, October 2004, Taylor & Francis

    Dr Mitchell R Smith

  35. Predicting treatment response in non-Hodgkin’s lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine1

    Article • Academic Radiology, April 2004, Elsevier

    Dr Mitchell R Smith

  36. Phase I Study of Bryostatin-1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma

    Article • Clinical Lymphoma, December 2002, Elsevier

    Dr Mitchell R Smith

  37. Antisense oligonucleotides complementary to immunoglobulin sequences of BCL-2/immunoglobulin fusion transcript induce apoptosis of t(14;18) lymphoma cells

    Article • British Journal of Haematology, December 2000, Wiley

    Dr Mitchell R Smith

  38. Antisense oligonucleotides complementary to immunoglobulin sequences of BCL-2/immunoglobulin fusion transcript induce apoptosis of t(14;18) lymphoma cells

    Article • British Journal of Haematology, December 2000, Wiley

    Dr Mitchell R Smith

  39. Differentiating Large Cell Lymphoma from Indolent Small B-Cell Lymphoma in Fine Needle Aspirates Using p53, PCNA and Transformed Lymphocyte Count

    Article • Acta Cytologica, January 2000, Karger Publishers

    Dr Mitchell R Smith

  40. Utilization of fine-needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma

    Article • Cancer, August 1998, Wiley

    Dr Mitchell R Smith

  41. Utilization of fine‐needle aspiration cytology and flow cytometry in the diagnosis and subclassification of primary and recurrent lymphoma

    Article • Cancer, August 1998, Wiley

    Dr Mitchell R Smith

  42. Non-Hodgkin's lymphoma

    Article • Current Problems in Cancer, January 1996, Elsevier

    Dr Mitchell R Smith

  43. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11)

    Article • Cancer Genetics and Cytogenetics, October 1993, Elsevier

    Dr Mitchell R Smith

  44. Bone marrow necrosis in lymphoma studied by magnetic resonance imaging

    Article • American Journal of Hematology, May 1992, Wiley

    Dr Mitchell R Smith

  45. A human b-cell lymphoma line with a de novo multidrug resistance phenotype

    Article • Cancer, March 1992, Wiley

    Dr Mitchell R Smith